Goal attainment in patients referred to a telephone-based dyslipidemia program

American Journal of Health-System Pharmacy

Volumn 62, Issue 15, 2005, Pages 1586-1591

  Palmieri, James ^a,b   Redline, Shannon ^c,d   Morita, Richard ^e  

^a Catholic Healthcare West   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c Safeway Inc   (United States)

^d Thomas J Long School of Pharmacy and Health Sciences   (United States)

^e PFIZER INC   (United States)

Author keywords

Diabetes mellitus; Disease management; Hyperlipidemia; Interventions; Patient information; Telephone

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; DIABETES MELLITUS; DISEASE MANAGEMENT; DYSLIPIDEMIA; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PATIENT INFORMATION; PATIENT REFERRAL; PRIORITY JOURNAL; REVIEW; TELEPHONE;

EID: 23044493097     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040343     Document Type: Review

References (23)

1. Lee TH, Cleeman JI, Grundy SM et al. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA. 2000; 283:94-8.
2. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999; 341:410-8.
3. Tonkin A, Simes RJ. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.
4. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998; 279: 1615-22.
5. Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004; 5:81-7.
6. Ross SD, Allen IE, Connelly JE et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999; 159:1793-802.
7. Shepard J, Blauw GJ, Murphy MB et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomized controlled trial. Lancet. 2002; 360:1623-30.
8. Sever PS, Dahlof B, Wedel H et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003; 361:1149-58.
9. Shepard J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333: 1301-7.
10. Jukema JW, Bruschke AV, VanBroven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995; 91:2528-40.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2846-97.
12. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285:1711-8.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1838-9.
14. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
15. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.
16. Fox J, Jones K. Lipid-lowering interventions in managed care settings. Am J Med. 2001; 110(suppl 6A):24s-30s.
17. Brown AS, Cofer LA. Lipid management in a private cardiology practice (the Midwest Heart Experience). Am J Cardiol. 2000; 85(3A):18A-22A.
18. Walsh MN, Simpson RJ, Wan GJ et al. Do disease management programs for patients with coronary heart disease make a difference? Experience of nine practices. Am J Manag Care. 2002; 8:937-46.
19. Allen JK, Blumenthal RS, Margolis S et al. Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial. Am Heart J. 2002; 144:678-86.
20. Pearson TA, Laurora I, Chu H et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160:459-67.
21. Higley J, Kelman S, Palmieri J et al. Evaluation of a regional lipid management program. Paper presented at 2001 Preventive Cardiovascular Nurses Association Symposium and Exposition. Dallas, TX; 2001 Oct 19.
22. Latts LM. Assessing the results: Phase-1 hyperlipidemia outcomes in 27 health plans. Am J Med. 2001; 110(suppl 6A):17S-23S.
23. Foley KA, Simpson RJ, Crouse JR III et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003; 92:79-81.